BRUKINSA® Waldenström’s macroglobulinaemia (WM)

This is a promotional website intended for healthcare professionals in the UK and Ireland only.

BRUKINSA® as monotherapy is indicated for the treatment of adult patients with WM who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.1

The efficacy and safety of BRUKINSA in the treatment of WM were demonstrated in the ASPEN study, a phase 3, randomised, open-label, multicentre study comparing BRUKINSA with ibrutinib.2

Results from the ASPEN study demonstrate that BRUKINSA is an effective treatment for WM.2 The primary endpoint in the ASPEN study was the proportion of patients in Cohort 1 (MYD88L265P) who achieved a very good partial response (VGPR) or complete response (CR), as assessed by an independent review committee (IRC).2 Whilst the primary endpoint was not met, treatment with BRUKINSA was associated with a trend towards better disease control and greater improvement in quality of life measures, versus ibrutinib.2 BRUKINSA was generally well tolerated, with fewer treatment discontinuations and dose reductions compared with ibrutinib.2

The use of BRUKINSA for the treatment of adult patients with WM who have received at least one prior therapy is supported by the National Institute of Health and Care Excellence (NICE).3

Both the Scottish Medicines Consortium (SMC) and the Health Service Executive (HSE) in Ireland have approved reimbursement for BRUKINSA for the treatment of adult patients with WM who have received at least one prior therapy, or as first-line treatment for patients unsuitable for
chemo-immunotherapy.4,5

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at www.mhra.gov.uk/yellowcard.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA.

All adverse events (UK and Ireland) should also be reported to BeiGene at [email protected]; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

September 2023 [0823-BRU-PRC-163]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not